Home Tags AbbVie

Tag: AbbVie

Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

AbbVie Demonstrates Progress in Oncology Research at ASCO 2016

Chemotherapy remains the standard of care in the treatment of many types of cancer. However, one of the problems with chemotherapeutics is that it...

Expanding Oncology Presence: AbbVie Acquires Stemcentrx

AbbVie, a global biopharmaceutical company has agreed to acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), also known as SC16LD6.5, which is currently...

CytomX and AbbVie Jointly Develop and Commercialize Probody-drug Conjugates Directed...

Antibody-drug conjugates or ADCs combine the cytotoxic potential of chemotherapeutic drugs with the specificity of monoclonal antibodies.  One of the critical parameters effecting the efficacy,...

AbbVie Acquires Small API Site in Singapore

AbbVie, a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott, has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in...
FDA_EMA

Phase I Trial Results in GBM Lead to Orphan Drug Designation...

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiform.

X